T A B L E O F C O N T E N T S
On average, treatment effect estimates for subjective outcome events assessed by onsite assessors did not differ from those assessed by ACs. Results of subgroup analysis showed an interaction according to the blinded status of onsite assessors and the process used to submit data to AC. These results suggest that the use of ACs might be most important when onsite assessors are not blinded and the risk of misclassification is high. Furthermore, research is needed to explore the impact of the different procedures used to select events to adjudicate.
P L A I N L A N G U A G E S U M M A R Y

Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates
It is widely recommended that multicentre randomised controlled trials (RCTs) should have a central process for assessing whether or not a patient has had an event, rather than relying solely on the outcomes reported by assessors at the relevant site where the decision might be subjective. These Adjudication Committees (ACs) are commonly used, especially in large trials. For example, the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) recommend assessment of events by such committees to harmonise and standardise outcome assessment across a trial. However, there is a need for evidence to justify the use of ACs and to decide on how central adjudication of clinical events should be conducted. This is the first large meta-analysis across medical areas to evaluate the impact of central adjudication on the estimates for treatment effect produced by RCTs. We investigated whether using the event data from ACs produced different treatment effect estimates than the data from onsite for subjective outcomes in RCTs.
We defined an AC as a committee of clinical experts in a specific medical area that seeks to harmonise and standardise the outcome assessment; whereas onsite assessors would be investigators, research nurses, data collectors, or patients themselves doing an onsite evaluation of the occurrence of the outcome during the RCT. Onsite assessors may, or may not, be blinded to the treatment assigned. We included all reports of RCTs and meta-analyses of published RCTs that reported the same subjective binary clinical event outcome assessed by both an onsite assessor and an AC.
We combined the findings of 47 RCTs (275,078 patients) in our systematic review and meta-analysis in order to see if there is a difference between the results from ACs and from onsite assessment. Our results showed that treatment effect estimates of subjective clinical events did not differ, on average, from those assessed by ACs. When we divided the data into whether or not the onsite assessors knew the patient's allocated treatment in the RCT and the various ways of submitting data to ACs, we found that there might be important differences between onsite assessment and ACs depending on which methods are used. Our findings, which are up to date as of August 2015, raise important uncertainty about whether ACs are being used appropriately across all RCTs.
B A C K G R O U N D
An adjudication committee (AC) consists of a group of clinical experts in a specific medical area who validate the assessment of outcomes in a randomised controlled trial (RCT). Central adjudication of clinical events is recommended and commonly used in large multicentre RCTs (Stuck 2014) . For example, the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) recommend assessment of events by ACs to harmonise and standardise outcome assessment. ACs are usually blinded to the assigned treatment, regardless of whether the trial itself is conducted in a blinded manner. Such committees are considered valuable when outcomes are subjective and when the intervention is not delivered in a blinded fashion (Bellamy 1997) , and ACs are used to reduce bias and to ensure more precise classification of events (Granger 2008) .
Detection bias, which is also called ascertainment bias or observer bias, might be expected with onsite assessment, mainly due to the knowledge of the allocated interventions by the assessor (Higgins 2011) . This implies, especially for subjective binary outcomes, that there is a high risk of a biased effect estimates in RCTs which might exaggerate the effect estimates (Hróbjartsson 2012) . Therefore, an AC might be a useful way to address such bias.
Description of the problem or issue
The importance of ACs has been advocated in some studies and challenged in others. Some studies have shown that the classification of events could change after outcome assessment by an AC (Naslund 1999; Mahaffey 2001b; O'Connor 2005 
Description of the methods being investigated
We investigated the impact of the use of an AC on treatment effect estimates in RCTs. An AC is defined as a committee of clinical experts in a specific medical area that harmonises and standardises the outcome assessment. The onsite assessors represent investigators, research nurses, data collectors, or patients themselves doing an onsite evaluation of the occurrence of the outcome during the RCT. Onsite assessors may, or may not, be blinded to the treatment assigned.
How these methods might work
The AC aims to increase the reliability of assessing outcomes by a more accurate assessment of events, discarding events that are potentially not valid and minimising bias (Boutron 2006; Boutron 2007; Dechartres 2009; Vannabouathong 2012) . Hence, an AC would provide a systematic, unbiased, and independent assessment of outcomes by using a set of predefined criteria developed before the initiation of the RCT. Adjudication of outcomes should theoretically minimise bias through a blinded outcome assessment (without knowledge of the patient's allocated treatment) and reduce the variance that would exist between different site investigators through a standardised assessment with clearly defined endpoint definitions (Vannabouathong 2011 
Why it is important to do this review
The use of ACs in RCTs is frequent, particularly in some medical areas such as cardiology. For example, in a sample of 969 trials of venous thromboembolism, 69% reported the use of an AC (Stuck 2014). In addition, in a sample of RCTs published in high-impact journals, the use of AC was reported in 33% of the 314 trials, ranging from 9% of 34 RCTs in infectious diseases to 81% of 75 RCTs in cardiology (Dechartres 2009). The adjudication process can be costly because it involves identifying the cases to be adjudicated, collecting all the data to be adjudicated (case report forms, biological tests, radiography and other complementary tests, etc), anonymising and masking the data, identifying and inviting the adjudication members, training adjudication members, adjudicating the data, organising regular consensus meetings, and so forth. Adjudication outcome assessment is highly recommended for studies that include subjective outcomes when blinding is not possible, and there is clear evidence that unblinded outcome assessment of subjective outcomes will overestimate treatment effect estimates (Wood 2008; Hróbjartsson 2012; Savovi 2012) . To our knowledge, no comprehensive systematic review across medical areas has been published on this topic.
O B J E C T I V E S
We sought to assess the impact of adjudication committee (ACs) versus onsite outcome assessment on treatment effect estimates for subjective outcomes in randomised controlled trials (RCTs).
Criteria for considering studies for this review
Types of studies
We included all reports of RCTs and any published RCTs included in reviews and meta-analyses (using these as a source of data on the individual studies) that reported the same subjective binary clinical event outcome assessed by both an onsite assessor and an AC. So, to be eligible, a study had to provide data to calculate the odds ratio (OR) for onsite assessment and for AC separately. We excluded RCTs comparing AC assessment with administrative data (e.g., death certificates) or with outcome assessment by a local outcome committee. We also excluded RCTs using the same treatment in the two allocated groups. Furthermore, reports describing a specific complementary examination such as phlebography (evaluated only by imaging) were excluded. We also excluded RCTs in which it is unclear which intervention is "experimental" and which is "control" because such RCTs did not allow us to determine the direction of any bias on the effect estimate. We did not place any restrictions on the number of centres included in the RCTs selected for the review. Single-and multicentre trials were eligible for inclusion.
Types of data
Eligible studies reported a subjective binary clinical event outcome. An outcome was considered "subjective" if it was based on an observer exercising judgment while assessing an event or state and could consequently be influenced by the assessor's knowledge of the allocated treatment (Moustgaard 2014). Objective outcomes were those determined without exercising judgment. We selected trials with subjective clinical events because there is evidence that blinding of outcome assessors is particularly important for subjective outcomes, but not for objective outcomes (Wood 2008; Hróbjartsson 2012; Savovi 2012) .
Types of methods
All eligible RCTs directly compared central versus onsite assessment for the same outcome.
Types of outcome measures Primary outcomes
Our primary outcome was the impact of the AC on the treatment effect estimate for a subjective binary clinical outcome in the relevant RCT, compared to onsite assessment. Two review authors (LAND, AY) independently selected one outcome from the article reporting each included RCT. This outcome will have been assessed by both an onsite assessor and an AC, and the data needed to have been provided for each treatment group. The decision to label an outcome as "subjective" was made by two trained clinical epidemiologists (LAND, AY). Disagreements were resolved by discussion with a third review author (IB). We only referred to the adjudication of outcomes, not to the adjudication of other data in the trial (e.g., baseline characteristics). If the primary outcome was a composite of objective and subjective outcomes, we selected at least one subjective outcome component that had been assessed by both an onsite assessor and an AC. If several outcomes in a RCT were assessed by an onsite assessor and an AC, we selected only one outcome. For this purpose, we first selected all efficacy outcomes when available. If several efficacy outcomes were available, we selected the efficacy outcome(s) reported as primary outcome(s) of the RCT (i.e., as clearly stated in the RCT article, described in the study objectives, or used for the sample size calculation). If none or several were reported as primary outcome(s), we selected the most clinically relevant outcomes, and among them the outcome with the most events. We used the same selection process if the outcomes assessed by both an onsite assessor and an AC were only safety outcomes. If several time points were reported for an outcome, we selected the first time point after the end of treatment.
Secondary outcomes
There were no secondary outcomes for this review because our aim was to evaluate the impact of AC versus onsite assessment on the treatment effect estimates.
Search methods for identification of studies Electronic searches
We searched a variety of standard databases (Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, PsycINFO, CINAHL) up to 18 March 2014 and updated our search most recently in August 2015 using the search strategies listed in Appendix 1. We also searched the full-text database (Google Scholar) with commonly used terms including adjudication committee, central adjudication, endpoint committee, clinical event committee, outcome committee, critical event committee.
Searching other resources
We checked the references of included studies to identify additional relevant reports (Horsley 2011).
Data collection and analysis
If any RCTs identified in our initial search only reported the results of clinical events assessed by an AC, we sought the authors' email addresses and contacted them to ask whether they had collected onsite outcome data and whether they could provide these data.
Selection of studies
One review author (LAND) screened all titles, abstracts and text fragments retrieved from the databases. The information selected was reviewed by a second review author (CB) to confirm relevance to the review. The review authors obtained the full-text study reports relating to every potentially eligible record. If the selected report was an ancillary analysis of the RCT comparing onsite assessor and AC assessments, the primary report of the RCT was also retrieved. When the selected report was a report of a meta-analysis pooling data of individual RCTs in which the treatment effect estimates from the AC and the onsite assessor was compared, the primary reports of the included RCTs were systematically searched for and evaluated. If primary reports of these RCTS were not available, we collected data from the meta-analysis and reported the total number of events in each treatment group resulting from the onsite assessor and AC assessment for each RCT. However, we excluded the RCTs in the meta-analysis report if the meta-analysis reported only combined effect estimates, and did not provide the effect estimates for each RCT separately.
Data extraction and management
We used a pre-tested data extraction form (Appendix 2) to collect general characteristics and outcome data of the eligible reports. Two review authors (LAND, CB) extracted the following data independently and disagreements were resolved by discussion. General characteristics of the RCT: medical speciality, funding source, experimental intervention, comparator. We considered that onsite assessors were blinded if the study was reported as a double-blind study, a similar placebo procedure was used, a double-dummy procedure was used, or a specific method was reported to blind the onsite assessor when patients and care providers were not blinded. Data on the functioning of the AC: blinding status of the AC in terms of allocated treatment and to the onsite assessment, training and independence of AC members, and information provided to the AC. We extracted the method for selecting cases to adjudicate (i.e., whether this used events identified by the onsite assessor, computer algorithms to identify suspected events, adjudication of all patients randomised and the assessment of all deaths in the context of determining a specific cause of death). Outcome data: total number of events in each randomised group resulting from onsite-assessor and AC assessments. When possible, we extracted paired patient-level data for onsite-assessor and AC assessment and constructed a 2×2 table (event/no event x onsite/ AC) for the experimental group and a corresponding table for the control group. For RCTs with more than two groups, we combined the results for the experimental groups. We estimated treatment effects as odds ratios (ORs). Outcome events were recoded in all RCTs such that an OR < 1 indicates benefit from the experimental treatment.
Assessment of risk of bias in included studies
A possible risk of bias for the comparison of onsite assessment versus ACs is linked to the method used to select cases to adjudicate. This selection could be biased if it is not blinded to the allocated treatment, for example if the events to be adjudicated were identified by the unblinded onsite assessor. To investigate this, we collected the method for selecting cases to adjudicate. These methods were classified as "events identified independently of onsiteassessor assessment" if 1) events to be adjudicated were identified with a computer algorithms, 2) all patients randomised were adjudicated, or 3) all deaths were adjudicated when the outcome of interest was a specific cause of death. Selection methods were considered as low risk of bias if the onsite assessor was blinded or if events were identified independently of onsite-assessor assessment. If events were identified by unblinded onsite-assessors, we considered this to have a high risk of bias. We used unclear risk of bias if the methods of selection and blinded status of onsite assessors were not clear.
Measures of the effect of the methods
We summarised the effects by comparing the effect estimates for the same clinical event outcome in each RCT that were calculated with the outcome data from the onsite assessor versus the same analysis using outcome data from the AC. For each RCT, we calculated the ratio of ORs (ROR) as the OR from onsite assessors relative to the corresponding OR from the AC (ROR = OR Onsite / OR AC ). An ROR < 1 indicated that onsite assessors generated larger effect estimates in favour of the experimental treatment than ACs.
Unit of analysis issues
Because the onsite assessor and the AC classified outcome events for the same study population, the two corresponding estimates were correlated. The standard error of the logROR was calculated as the square root of the sum of the variance of the logOR for AC and onsite assessment. It was our intention to use the delta method so that the standard error of the logROR took into account the correlation between onsite and AC assessment (Bagos 2012; Hróbjartsson 2012), but we were unable to do this because the data required to estimate the covariance of the two correlated logORs were not available.
Dealing with missing data
When data were incomplete (e.g., authors reported the total number of events resulting from the onsite-assessor and AC assessment but did not provide the data separately for each randomised group), we wrote to the corresponding author to ask for the results by group.
Assessment of heterogeneity
Heterogeneity was assessed by the I 2 statistic and the betweentrial variance τ ². I 2 was the proportion of total variation between the studies attributable to differences between RCTs rather than to sampling error (chance), with values < 30% representing low heterogeneity, ≤ 60% moderate heterogeneity, and > 60% high heterogeneity.
Assessment of reporting biases
To minimise reporting bias, for all RCTs identified in our initial search which were excluded because they only reported the results of clinical events assessed by an AC, we contacted the corresponding author to request the data for onsite assessors. We explored the impact of these data on the results in a sensitivity analysis. We did not intend to perform any other specific assessment of reporting bias because the statistical tools commonly used to assess reporting bias and related small-study effects in meta-analysis (in particular the funnel plot) have not been transposed or extended to meta-epidemiological studies.
Data synthesis
We pooled the individual RORs using a DerSimonian and Laird random-effects meta-analysis (DerSimonian 1986), and reported the results in a forest plot with 95% confidence intervals (CIs). The decision to pool the RORs was based on the assessment of statistical heterogeneity and methodological diversity. If data combination was deemed inappropriate, we presented the results of individual studies in a forest plot (without a meta-analysis) and discussed them. We considered the point estimate of the ROR significant at P < 0.05 if the 95% CI did not include the value 1.
Subgroup analysis and investigation of heterogeneity
We tested the interaction between the ROR and the blinding status of onsite assessors and ACs as well as the method used to select cases to adjudicate (events identified by or independent of onsiteassessor assessment).
Sensitivity analysis
We conducted a sensitivity analysis to explore the impact of unreported data on our results.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
Results of the search
The screening process is described in Figure 1 . We examined 1210 full-text articles based on 7855 hits in standard databases and 1893 hits in the full-text database. After reading the full-text articles, we selected 25 reports of RCTs and four reports of meta-analyses which had included 21 RCTs. Two reports of RCTs were identified from the personal collections of the authors. Of the 874 fulltext articles reporting only results for the AC, we obtained an email address for corresponding authors of 496 trials; 106 authors responded and we obtained the data for 10 RCTs. Finally, we included 47 RCTs (with a total of 275,078 patients) in our metaanalysis. Table 1 shows the baseline characteristics of the 47 RCTs included in the meta-analysis. The median sample size was 3449 [interquartile range 1506 to 10,000], 83% (n = 39) of RCTs were in the field of cardiology, 89% (n = 42) were multicentre RCTs, and 94% were sponsored completely or partially by industry. The outcomes selected for assessment were mainly the RCT's primary outcomes (n = 39, 83%). Many RCTs (n = 32; 68%) studied a composite outcome. Most of these composite outcomes included subjective outcomes only (n = 35; 75%), but 25% (n = 12) were a composite of subjective and objective outcomes. Details related to the AC are in Table 2 . For 40 RCTs (85%), ACs were reported as blinded to the treatment allocated. The AC evaluated mainly suspected cases (failure events) identified by the onsite assessor (n = 37; 79%). For 35 RCTs (75%), the onsite assessor was blinded to the treatment allocated.
Included studies
Excluded studies
We excluded 11 studies because they did not provide the necessary data to calculate the OR for onsite assessment and for AC separately (Characteristics of excluded studies). We contacted the corresponding authors of these 11 studies but did not receive any responses after at least two reminders.
Risk of bias in included studies
A possible risk of bias is linked to the method for selecting cases to adjudicate, especially when the relevant events are identified by the unblinded onsite assessor. Overall, 35 RCTs (75%) reported using blinded onsite assessors. Among the 12 RCTs with unblinded onsite assessors, events submitted to ACs were identified by the unblinded onsite assessors in 10 RCTs. In the two other unblinded RCTs, events submitted to ACs were identified independently of the onsite assessors.
Effect of methods
Treatment effect estimates from the onsite assessment and the ACs are shown in Figure 2 for the 47 included RCTs. We found no difference, on average, in treatment effect estimates between onsite assessment and ACs. The combined ROR was 1.00 (95% CI 0.97 to 1.04), with no heterogeneity (I 2 = 0%, τ ² = 0%) (n = 47 RCTs). Furthermore, we found no evidence of interaction by blinding status of onsite assessors ROR = 1.00, 95% CI 0.96 to 1.04 with blinded onsite assessors (n = 35 RCTs) and with unblinded onsite assessors (ROR 1.08, 95% CI 0.94 to 1.23, 12 RCTs); P = 0.07 (Table 3 ).
Figure 2. Impact of adjudication committee assessment on estimated intervention effects in randomised clinical trials measured as ratio of odds ratios (odds ratio based on onsite outcome assessment divided by odds ratio based on adjudication committee assessment)
However, subgroup analysis showed a statistically significant interaction by blinding status of onsite assessor and the process for submitting data to the AC. The combined ROR was 1.00 (95% CI 0.96 to 1.04, I 2 = 0%, 35 RCTs) with blinded onsite assessors; 0.76 (95% CI 0.48 to 1.21, I 2 = 0%, two RCTs) with AC-assessed events identified independent of unblinded onsite assessors; and 1.11 (95% CI 0.96 to 1.27, I 2 = 0%, 10 RCTs) with AC-assessedonly events identified by unblinded onsite assessors ; P = 0.03 ( Figure 2 , Table 3 ).
D I S C U S S I O N Summary of main results
We performed a meta-analysis of 47 randomised controlled trials (RCTs) (275,078 patients) to compare treatment effect estimates of subjective clinical events assessed by onsite assessors and by ACs. The combined ROR was 1.00 (95% CI 0.97 to 1.04). Results of subgroup analyses showed an interaction by blinding status of onsite assessors and the process used to submit data to ACs, with an increase in the effect estimate for the experimental treatment with onsite assessment compared to AC when the events were submitted by unblinded onsite assessors compared to when they were submitted by blinded onsite assessors or submitted independently of unblinded onsite assessors.
Overall completeness and applicability of evidence
The included RCTs are mainly large multicentre trials in cardiology. These results should be extrapolated to other medical areas with caution, but the included RCTs are representative of trials using ACs (Dechartres 2009; Stuck 2014) .
Quality of the evidence
Our review has several strengths. First, our search strategy allowed for identifying trials with no restriction on medical area. Second, we identified a large sample of high-quality RCTs with a large sample of patients in total. Third, our study featured low risk of confounding because of the direct comparison of onsite and AC assessment of the same outcome in the same study involving the same patients. Finally, the large number of included studies allowed us to perform a prespecified subgroup analysis related to the blinding status of onsite assessors and the submission of data to ACs.
Potential biases in the review process
Our review has some limitations. First, we cannot exclude a selective reporting bias, and investigators might be less prone to report the results of both AC and onsite assessors if the results differed. Furthermore, 11 RCTs (Characteristics of excluded studies) could not be included in the meta-analysis because data were not available to compare the results for the randomised groups even though we contacted the corresponding authors of these RCTs to request the missing data. In contrast, we contacted authors reporting only outcomes assessed by ACs and obtained estimates for the onsite assessor for 10 RCTs. Second, the outcomes selected had variable levels of subjectivity, with 25% concerning composite outcomes including both subjective and objective outcomes (such as death). Third, we identified only two RCTs that had used unblinded onsite assessment, a blinded AC and an unbiased method for selecting cases to be adjudicated. Finally, we could not incorporate the correlation between effect estimates for ACs and onsite assessors because the data required to estimate the covariance were not available.
Agreements and disagreements with other studies or reviews
The largest previous study in this topic was published by Pogue and colleagues (Pogue 2009). They selected 10 RCTs conducted at the Population Health Research Institute in the field of cardiology. They did not detect any effect of event adjudication on the treatment effect estimates and raised the need to conduct more systematic analyses of the effect of the event adjudication in other trials to determine if this process is worthwhile. Other researchers have outlined the importance of ACs showing that misclassifications between onsite-assessor and AC assessment can be frequent. However, these misclassifications may not be biased and might not lead to differences in treatment effect estimates (Hata 2013 , Kirwan 2007 . Because establishing and running an AC is time and resource consuming, some argue that ACs should be implemented only when the risk of misclassification is high (i.e., when onsite assessors are not blinded and the outcomes are subjective) (Granger 2008 , Dechartres 2009 The question of the mode of data submission to the AC is important. In 79% of the RCTs included in our meta-analysis, the method used to select cases to adjudicate was suspected events identified by the onsite assessor. Consequently, events that the onsite assessors had missed would not have been adjudicated. Therefore, when onsite assessors are not blinded, the estimated treatment effect by the AC could be biased because the AC will evaluate a biased sample of events identified by unblinded onsite assessors. The use of an AC could provide a false security because it does not control for the differential misclassification from onsite assessors.
This issue was raised for the RECORD study and prompted the US FDA to modify the method for selecting cases to be adjudicated (Psaty 2010; Lopes 2013), although the "readjudication" of RECORD data also raised some concerns (Nissen 2013).
A U T H O R S ' C O N C L U S I O N S Implication for methodological research
Further research is needed to explore the impact of the different procedures used to select events to adjudicate. 
C H A R A C T E R I S T I C S O F S T U D I E S
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identified by onsite assessor who was not blinded to allocated treatment
Büller 2012
Methods RCT comparing oral rivaroxaban versus enoxaparin for the treatment of symptomatic pulmonary embolism Data 4833 patients were randomised (2420/2413, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator non blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was recurrent venous thromboembolism. It was the study's primary outcome Notes Data related to the number of events in each treatment group resulting from onsiteassessment were obtained directly from the study authors
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identified by onsite assessor who was not blinded to allocated treatment 
CHARM 2003
Methods
RCT comparing candesartan versus placebo in patients with chronic heart failure and preserved left-ventricular ejection fraction Data 3025 patients were randomised (1514/1509, respectively in each treatment group), including two patients who mistakenly received randomisation numbers but had no other data recorded and never received study medication
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was admission to hospital for chronic heart disease or cardiovascular death. The study's primary outcome was cardiovascular death or admission to hospital for chronic heart failure Notes The study was identified because it was include in a review of six RCTs (Granger 2008) . Data related to the number of events in each treatment group resulting from onsiteassessor and AC assessments were extracted from this review
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identified by onsite assessor who was blinded to allocated treatment
CREATE 2005
Methods RCT comparing reviparin versus placebo in patients with acute myocardial infarction presenting with ST-segment elevation Data 15,570 patients were randomised (7780/7790, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was myocardial infarction or stroke at 7 days or death
Notes
The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue 2009). Data related to the number of events in each treatment group resulting from onsite-assessor and AC assessments were extracted from this meta-analysis on the primary outcomes of the included studies The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue 2009). Data related to the number of events in each treatment group resulting from onsite-assessor and AC assessments were extracted from this meta-analysis on the primary outcomes of the included studies
Risk of bias
Item
Authors' judgement Description
Risk of bias
Item
Authors' judgement Description
EPIC 1994
Methods RCT comparing c7E3 Fab bolus and infusion versus placebo in high-risk patients ongoing coronary angioplasty Data 2099 patients were randomised (1403/696, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was non fatal myocardial infarction or death from any cause. This was a prespecified composite of any of the following events in the first 30 days after randomisation
Notes
The study was identified because it was include in a review of six RCTs (Granger 2008) . Data related to the number of events in each treatment group resulting from onsiteassessor and AC assessments were extracted from this review 
EPIC 1994 (Continued)
Risk of bias
Item
Authors' judgement Description
Fiessinger 2005
Methods RCT comparing ximelagatran versus low molecular weight heparin and warfarin for the treatment of deep vein thrombosis Data 2528 patients were randomised (1258/1270, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was recurrent venous thromboembolism. The primary composite outcome was recurrent venous thromboembolism, bleeding, and mortality
Notes
Risk of bias
Item
Authors' judgement Description
Francis 2002
Methods RCT comparing ximelagatran versus warfarin for the prevention of thromboembolism after total knee arthroplasty Data 680 patients were randomised (348/332, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was total thromboembolism. The study's primary outcome was the incidence of deep venous thrombosis (proximal or distal) or pulmonary embolism
Francis 2002 (Continued)
Item
Authors' judgement Description
Gulizia 2008
Methods RCT designed to test the non-inferiority of class IC antiarrhythmic drugs to amiodarone, in patients paced for sinus node disease Data 176 patients were enrolled: 70 patients were discharged on amiodarone, 75 patients were discharged on class IC agents (38 on propafenone and 37 on flecainide), and 31 were discharged on sotalol
Comparisons
Onsite assessment (local investigator non blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was a composite outcome of death, permanent atrial tachyarrhythmias, cardiovascular hospitalisation, atrial cardioversion or antiarrhythmic drug change. This was the study's primary outcome Notes Data related to the number of events in each treatment group resulting from onsiteassessment were obtained directly from the study authors
Risk of bias
Item
Authors' judgement Description
GUSTO-IIb 1996
Methods RCT comparing recombinant hirudin versus heparin for the treatment of acute coronary syndromes Data 12,142 patients randomised (6069/6073, respectively in each treatment group. Patients were stratified according to the presence of ST-segment elevation on the base-line electrocardiogram (4131 patients) or its absence (8011 patients), with the latter characteristic considered to indicate unstable angina or non-Q-wave myocardial infarction
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment
GUSTO-IIb 1996 (Continued) Outcomes
The outcome selected was a composite outcome of myocardial infarction or reinfarction at 30 days or death from any cause. This was the study's primary outcome
Notes
The study was identified because it was included in a review of six RCTs (Granger 2008) . Data related to the number of events in each treatment group resulting from onsiteassessor and AC assessments were extracted from this review
Risk of bias
Item
Authors' judgement Description
Hata 2013
Methods RCT assessing the effects of the routine administration of an angiotensin-converting enzyme inhibitor-diuretic combination on serious vascular events in patients with diabetes, irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs Data 11,140 were randomised (5569/5571, respectively to perindopril-indapamide and to placebo)
Comparisons
Outcomes
The outcome selected was a composite outcome of major macro (non fatal myocardial infarction, non fatal stroke and cardiovascular death) and microvascular events (new or worsening nephropathy and retinopathy). This was the study's primary outcome
Notes
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identified by onsite assessor who was blinded to allocated treatment 
Hawkey 2007
Methods
RCT comparing lumiracoxib versus nonsteroidal anti-inflammatory drugs (naproxen or ibuprofen) in patients with osteoarthritis Data 18,325 patients were randomised and 18,244 received at least 1 dose of study medication: lumiracoxib (9117 patients), naproxen (4730 patients), oribuprofen (4397 patients)
Comparisons
Outcomes
The outcome selected was all definite or probable ulcer complications. This was the study's primary outcome
Notes
Risk of bias
Item
Authors' judgement Description
Hochman 2006
Methods RCT comparing percutaneous coronary intervention plus thrombolytic therapy versus thrombolytic therapy alone in patients who had total occlusion of the infarct-related artery 3 to 28 days after myocardial infarction Data 2166 patients were randomised (1082/1084, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator non blinded) versus assessment by an AC blinded to allocated treatment Outcomes The selected outcome was a composite outcome of reinfarction or heart failure or death from any cause.This was the study's primary outcome
Notes
Risk of bias
Item
Authors' judgement Description
HOPE 2000
Methods
RCT comparing ramipril versus placebo to prevent cardiovascular events in high-risk patients Data 9297 patients randomised (4645/4652, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was myocardial infarction, stroke or cardiovascular death
Notes
The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue 2009). Data related to the number of events in each treatment group resulting from onsite-assessor and AC assessments were extracted from this meta-analysis on the primary outcomes of the included studies
Risk of bias
Item
Authors' judgement Description
HOPE-2 2006
Methods RCT comparing folic acid plus vitamin B versus placebo to prevent cardiovascular events in high-risk patients Data 5522 patients randomised (2758/2764,) respectively in each treatment group)
Comparisons
Notes
Risk of bias
Item
Authors' judgement Description
IMPACT-II 1997
Methods
RCT comparing eptifibatide versus placebo to prevent cardiovascular events in high-risk patients Data 4010 patients randomised (2682/1328, respectively in each treatment group)
Comparisons
Outcomes
The outcome selected was a 30-day composite of myocardial infarction, coronary stent implantation, percutaneous revascularisation or death. This was the study's primary outcome
Notes
The study was identified because it was include in a review of six RCTs (Granger 2008) . Data related to the number of events in each treatment group resulting from onsiteassessor and AC assessments were extracted from this review
Risk of bias
Item
Authors' judgement Description
Kirwan 2007
Methods RCT investigating the effect of the calcium antagonist nifedipine versus placebo on longterm outcome in patients with stable angina pectoris Data 7797 patients were randomly allocated study drug with 7665 patients included in intention-to-treat analyses (3825/3840, respectively in nifedipine and placebo group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was a composite outcome of acute myocardial infarction, refractory angina, stroke or death. This was the study's primary outcome
Notes
Risk of bias
Item
Authors' judgement Description
McMurray 2006
Methods
RCT comparing the effect of valsartan monotherapy versus valsartan plus captopril versus captopril monotherapy on atherosclerotic events in patients who had acute myocardial infarction The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue 2009). Data related to the number of events in each treatment group resulting from onsite-assessor and AC assessments were extracted from this meta-analysis on the primary outcomes of the included studies
Risk of bias
Item
Authors' judgement Description
OASIS-2 1999
Methods RCT comparing the effects of recombinant hirudin (lepirudin) versus heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation Data 10,141 patients randomised (5058/5083, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was myocardial infarction at 7 days or cardiovascular death
Notes
Risk of bias
Item
Authors' judgement Description
OASIS-5 2006
Methods RCT comparing fondaparinux versus enoxaparin in acute coronary syndromes Data 20,078 patients randomised (10,057/10,021), respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was refractory ischaemia or myocardial infarction at 9 days or death
Notes
Risk of bias
Item
Authors' judgement Description
OASIS-6 2006
Methods
RCT analysing the effects of fondaparinux, a factor Xa inhibitor, versus usual care on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction Data 12,092 patients randomised (6056/6036, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was reinfarction at 30 days or death.
Notes
Risk of bias
Item
Authors' judgement Description
OPPORTUNITY 2011
Methods RCT comparing human growth hormone versus placebo in haemodialysis patients Data 712 patients were randomised and 695 patients who received at least one dose of trial medication (346/349, respectively in each treatment group) were considered in the full analysis set Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was any cardiovascular event and death of any cause. The study's primary outcome was time to all-cause death Notes Data related to the number of events in each treatment group resulting from onsiteassessment were obtained directly from the study authors
Risk of bias
Item
Authors' judgement Description
PARAGON-B 2002
Methods RCT comparing lamifiban versus placebo in patients with acute coronary syndrome 
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identified through a computer algorithm
RECORD 2009
Methods RCT comparing rosiglitazone versus metformin plus sulphonylurea in patients with type 2 diabetes Data 4447 patients were randomised (2220/2227, respectively in each treatment group)
Comparisons
Onsite assessment (local investigator non blinded) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was myocardial infarction. The study's primary outcome was cardiovascular hospitalisation or cardiovascular death.
Notes
The study was identified because it was included in a review (Serebruany 2012) . Data related to the number of events in each treatment group resulting from onsite-assessor and AC assessments were extracted from this review
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identified by onsite assessor who was blinded to allocated treatment 
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? No All deaths were adjudicated for a specific cause of death.
Topol 1993
Methods RCT comparing atherectomy versus angiography in patients with coronary artery disease Data 1012 patients were randomised (512/500, respectively in each treatment group)
Comparisons
Onsite assessment (blinded local investigator) versus assessment by an AC blinded to allocated treatment 
Topol 1993 (Continued)
Outcomes
The outcome selected was myocardial infarction. The study's primary outcome was angiographic restenosis
Notes
Risk of bias
Item
Authors' judgement Description
Method for selecting cases to adjudicate? No All patients randomised were adjudicated.
Verhamme 2013
Methods RCT comparing TB-402 versus rivaroxaban for the prevention of venous thromboembolism after total hip replacement Data 632 patients were randomised (423/209, respectively in each treatment group)
Comparisons
Onsite assessment (blinded local investigator) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was total venous thromboembolism. This was study's primary outcome Notes Data related to the number of events in each treatment group resulting from onsiteassessment were obtained directly from the study authors
Risk of bias
Item
Authors' judgement Description
Wallantin 2009
Methods RCT comparing ticagrelor versus clopidogrel in patients with acute coronary syndromes Data 18,624 patients were randomised (9333/9291, respectively in each treatment group)
Comparisons
Onsite assessment (blinded local investigator) versus assessment by an AC blinded to allocated treatment Outcomes The outcome selected was myocardial infarction. The study's primary outcome was the time to the first occurrence of composite of death from vascular causes, myocardial infarction, or stroke
D A T A A N D A N A L Y S E S
This review has no analyses. 
A D D I T I O N A L T A B L E S
